Tru Niagen review: is it worth it?

What is Tru Niagen and who makes it?

Tru Niagen is the consumer supplement brand for Niagen, a patented and FDA-reviewed form of nicotinamide riboside chloride (NR) — a vitamin-B3 derivative that the body converts into nicotinamide adenine dinucleotide (NAD+). It is sold by Niagen Bioscience (Nasdaq: NAGE), the company previously known as ChromaDex, which holds the core patents and licenses on Niagen and funds much of the published research on the ingredient.

The standard product is a once-daily 300 mg vegetarian capsule. The company also sells a higher-dose Tru Niagen Pro 1,000 mg line aimed at people who want a larger NAD+ increase. NR was discovered as a NAD+ precursor in the lab of biochemist Charles Brenner, whose group published the first human pharmacokinetic study of the molecule (PMID 27721479, *Nature Communications* 2016).

It is worth naming the central conflict of interest up front: the manufacturer sponsors or co-authors a large share of the human trials on Niagen. The trials are real, peer-reviewed, and mostly well-designed, but readers should weigh industry funding when interpreting how findings are framed.

How does Tru Niagen work?

NAD+ is a coenzyme present in every living cell. It is essential for converting food into cellular energy (it shuttles electrons in the mitochondria), and it is consumed as a substrate by repair and signaling enzymes such as the sirtuins and PARPs that respond to DNA damage and metabolic stress. NAD+ levels in tissues are widely reported to decline with age and with metabolic stress, and the core hypothesis behind every NAD+ supplement is simple: if you replenish the precursor, you raise NAD+, and higher NAD+ might restore some age-related decline in cellular function.

Nicotinamide riboside is one of several precursors the body can use to build NAD+ through the salvage pathway. Niagen Bioscience's key bioavailability argument is that NR enters cells and is converted to NAD+ efficiently. The first-in-human study showed that single oral doses of 100, 300, and 1,000 mg produced dose-dependent increases in the blood NAD+ metabolome, and identified a metabolic signature (NAAD) confirming NR was being used to build NAD+ (Trammell et al., *Nature Communications* 2016, PMID 27721479).

The important caveat: raising blood NAD+ is the mechanism, not the outcome. A supplement can robustly move a biomarker without changing how you feel or how your body ages. That distinction runs through the rest of this review.

Does Tru Niagen actually raise NAD+? (The strongest evidence)

This is where the data are genuinely good. Multiple randomized, double-blind, placebo-controlled trials show Niagen reliably and substantially increases whole-blood NAD+.

The most informative is a randomized, double-blind, placebo-controlled trial in 140 healthy overweight adults aged 40–60 (133 completed) testing 100, 300, and 1,000 mg/day for eight weeks (Conze, Brenner & Kruger, *Scientific Reports* 2019, PMID 31278280). At day 14, blood NAD+ rose by roughly 22% at 100 mg, 51% at 300 mg, and 142% at 1,000 mg, and the increases were sustained through day 56. This is the basis for the brand's "increase NAD+ by over 50%" claim, which maps to the 300 mg dose.

An earlier randomized crossover trial in healthy middle-aged and older adults also found that 1,000 mg/day was well tolerated and reliably elevated NAD+ (Martens et al., *Nature Communications* 2018, PMID 29599478). Across the published literature, the bioavailability story is consistent: NR gets into the blood and raises NAD+ in a dose-dependent way.

So if your only question is "does it move the biomarker it claims to move?", the answer is clearly yes.

Does raising NAD+ produce real health benefits?

This is the honest weak point, and it is where independent analysis diverges most sharply from marketing.

For healthy people, the clinical evidence that higher NAD+ improves anything you would actually notice is limited and frequently null. The same 2018 crossover trial that confirmed NAD+ elevation reported a modest reduction in systolic blood pressure and aortic stiffness in a subgroup, but these were exploratory secondary findings, not a primary endpoint, and have not been robustly replicated. Critically, several rigorous trials designed specifically to test metabolic benefit have come back negative:

• In a placebo-controlled crossover trial, 1,000 mg/day of NR for 21 days in aged men raised the muscle NAD+ metabolome but did not improve mitochondrial bioenergetics (Elhassan et al., *Cell Reports* 2019, PMID 31447334).
• A randomized trial in obese, insulin-resistant men found no improvement in insulin sensitivity, mitochondrial function, or metabolic flexibility despite supplementation (Dollerup et al., *American Journal of Clinical Nutrition* 2018, PMID 29992272; follow-up work PMID 32463114).

The 2019 trial in 140 overweight adults likewise found NAD+ went up but reported no significant differences versus placebo in blood pressure, lipids, or clinical chemistry parameters over eight weeks (PMID 31278280).

There are more promising signals in specific patient populations — for example, manufacturer-supported work suggesting NR can reduce markers of inflammation, and early-phase trials in Parkinson's disease showing high-dose NR raises brain and blood NAD+ with hints of symptom benefit. But these are early, mostly small, and not the same thing as proving that a healthy 50-year-old who takes 300 mg a day will live longer, feel more energetic, or age more slowly.

Bottom line on efficacy: strong evidence it raises NAD+, weak-to-mixed evidence it changes meaningful health outcomes in healthy adults. There is currently no published long-term human trial demonstrating that NR slows aging or extends healthspan.

Is Tru Niagen safe? Side effects and regulatory status

Safety is the most reassuring part of the profile. Across trials, NR has been well tolerated, with adverse-event rates generally comparable to placebo and, notably, without the skin flushing caused by high-dose niacin (nicotinic acid). In the 140-person trial, the type, incidence, and severity of adverse events were similar across all doses and placebo (PMID 31278280). Higher doses up to 1,000–2,000 mg/day in trials have also been tolerated, and a Parkinson's study used 3,000 mg/day short-term.

When side effects occur they are usually mild and gastrointestinal — nausea, bloating, or stomach discomfort — plus occasional headache or fatigue.

On regulation, Niagen has an unusually clean paper trail for a supplement ingredient:

• It has been reviewed under the FDA's New Dietary Ingredient (NDI) notification program and has received GRAS (Generally Recognized As Safe) "no questions" status (FDA).
• It was approved as a Novel Food by the European Commission after a favorable EFSA safety opinion.
• It is permitted in complementary medicines by Australia's Therapeutic Goods Administration (TGA).

Important real-world caveats:

• "GRAS/safe" is not the same as "FDA-approved to treat or prevent any disease." No NAD+ supplement is.
• Safety data are mostly short-to-medium term (weeks to a few months). True multi-year safety in healthy users is not established.
• People who are pregnant or breastfeeding, on chemotherapy, or who have a serious medical condition should talk to a clinician first — NAD+ metabolism intersects with pathways relevant to cancer and other diseases, and the long-term consequences of chronically elevating NAD+ are not fully understood.

How should you take Tru Niagen?

The standard, evidence-anchored dose is 300 mg once daily — one capsule — which is the dose tied to the ~50% NAD+ increase. It can be taken with or without food; there is no strong evidence that timing matters, though some people take it in the morning. Tru Niagen Pro provides 1,000 mg for those targeting the larger (~142%) NAD+ increase seen in trials, but there is no good evidence that the larger NAD+ rise produces proportionally larger health benefits — so paying more for a bigger biomarker move is not clearly worth it for most healthy people.

NAD+ elevation appears within about two weeks of consistent daily use and is sustained with continued dosing. If you stop, levels return toward baseline.

What does Tru Niagen cost, and is it worth it?

At the manufacturer's listed prices, the 300 mg, 30-capsule bottle is about $49 (roughly $1.63/day), with larger bottles and a 20% subscription discount lowering that meaningfully:

• 30 capsules: ~$49 one-time / ~$39.20 on subscription
• 90 capsules: ~$127 one-time / ~$101.60 on subscription (about $1.13/day subscribed)
• 180 capsules: ~$244 one-time / ~$195.20 on subscription (about $1.08/day subscribed)

Prices on Amazon and through the official site vary, so check current listings. (Prices reflect the manufacturer's published figures and can change.)

Value verdict: You are paying a premium for the patented, clinically studied, third-party-clean ingredient and the strongest body of bioavailability data in the category. That premium buys confidence in *quality and NAD+ elevation*, not proof of a health payoff. Whether ~$1–1.60/day is "worth it" depends entirely on how much you value moving a biomarker whose downstream benefit in healthy people is still unproven.

How does Tru Niagen compare to NMN and other NAD+ boosters?

The main rival precursor is nicotinamide mononucleotide (NMN), heavily promoted in longevity circles. The two have a notable regulatory history: in November 2022 the FDA took the position that NMN was excluded from the supplement definition because it had been authorized for investigation as a drug. After an industry citizen petition and litigation, the FDA reversed course in 2025, concluding NMN qualifies as a dietary supplement ingredient (FDA letters, 2025; reported by NutraIngredients). The practical takeaway for buyers: NR (Niagen) has had a stable, well-documented regulatory status throughout, while NMN's status was contested for years.

On the science, the honest summary is that head-to-head human evidence that either precursor is clinically superior does not exist. Niagen Bioscience argues NR is more directly bioavailable; NMN proponents argue the reverse. Both raise NAD+ in humans; neither has proven a meaningful healthspan benefit in healthy people. Tru Niagen's genuine differentiators are the patent protection, FDA/EFSA/TGA regulatory clearances, and the largest published human trial base in the category — which matter for trusting what is in the bottle, even if they do not settle the efficacy question.

Cheaper generic NR and NMN powders exist, but they lack Niagen's IP, regulatory dossier, and (often) third-party purity verification, which is a real consideration in a supplement market with documented quality and label-accuracy problems.

Who should consider Tru Niagen, and who should skip it?

Reasonable candidates:

• People who specifically want to raise NAD+ with the most clinically characterized, regulator-reviewed NR product and are comfortable that the broader benefits are unproven.
• People who tolerate niacin poorly and want a flush-free B3-pathway option.

Who should probably skip it:

• Anyone expecting a documented anti-aging, energy, or weight/metabolic benefit — that claim is not supported by current human data.
• Anyone on a tight budget who could get more proven health return from sleep, exercise, and diet spending.
• People who are pregnant, breastfeeding, undergoing cancer treatment, or managing a serious illness without first consulting a clinician.

The bottom line on Tru Niagen

Tru Niagen is the most rigorously studied, cleanly regulated NAD+ booster on the market, and it does exactly what it most concretely promises: a daily 300 mg dose reliably raises blood NAD+ by roughly 50% within two weeks (PMID 31278280). That is a real, replicated effect, and the safety record over weeks-to-months is reassuring (FDA GRAS; EFSA Novel Food).

What it has not demonstrated is that raising NAD+ produces the anti-aging, energy, or metabolic improvements that drive most purchases — several well-designed trials in healthy and metabolically impaired adults found no benefit beyond the biomarker change, and there is no long-term human healthspan trial. If you understand and accept that you are buying a high-quality way to move a biomarker rather than a proven anti-aging intervention, Tru Niagen is a defensible, low-risk choice. If you want evidence that it will make you healthier, the science is not there yet.